BioShin

BioShin is a Shanghai-based biopharmaceutical company operating as an Asia-Pacific subsidiary of the U.S. firm Biohaven Pharmaceutical Holding Company Ltd. Established in 2018, BioShin's primary objective is to develop and commercialize Biohaven's late-stage clinical portfolio for patients in the Asia-Pacific region, excluding Japan. The company focuses on addressing the significant unmet medical needs in neurologic and neuropsychiatric diseases, such as migraine, which affects an estimated 90 million individuals in China alone.

The formation of BioShin was a strategic move by Biohaven to tap into the burgeoning Asia-Pacific healthcare market, driven by regulatory changes and a growing patient population. Initially led by Donnie McGrath, M.D., who transitioned from his role at Biohaven, the company appointed Karl Lintel as CEO in September 2020. Lintel brought extensive experience from his previous roles as President and General Manager of Bristol-Myers Squibb in China. The broader management team comprises veterans from major pharmaceutical companies like Pfizer, Sanofi, and Novartis, highlighting a deep well of international and regional expertise.

BioShin's business model centers on licensing and advancing Biohaven's drug pipeline. The company secured a significant milestone in September 2020 by closing a $60 million Series A funding round led by OrbiMed, with participation from other notable healthcare investors. This capital infusion was earmarked to fund the build-out of its operations in China and to advance clinical trials for key product candidates. The company's core activity is conducting clinical trials to gain regulatory approval for these drugs in markets like China and South Korea. A primary product in its portfolio is rimegepant (marketed as Nurtec ODT in the U.S.), an orally administered treatment for acute migraine. BioShin has been conducting a Phase 3 trial for rimegepant in China and South Korea. The company is also advancing trials for troriluzole, a treatment for the rare genetic movement disorder Spinocerebellar Ataxia (SCA).

Keywords: biopharmaceutical, neurology, neuroscience, Asia-Pacific, China healthcare, clinical development, drug commercialization, Biohaven subsidiary, migraine treatment, rimegepant, Nurtec ODT, Spinocerebellar Ataxia, troriluzole, neuro-immune diseases, Series A funding, OrbiMed, late-stage clinical trials, CNS disorders, drug pipeline, pharmaceutical partnerships